Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 “STARD Compliant”

@inproceedings{MartinezUseros2015IdentificationOP,
  title={Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 “STARD Compliant”},
  author={Javier Martinez-Useros and Tihomir Georgiev-Hristov and Aurea Borrero-Palacios and M. J. Fernandez-Ace{\~n}ero and Mar{\'i}a Rodr{\'i}guez-Rem{\'i}rez and Laura del Puerto-Nevado and Arancha Cebri{\'a}n and M. T. Gomez del Pulgar and Alicia Cazorla and Ricardo Vega-Bravo and Nuria P{\'e}rez and Angel Celdr{\'a}n and Jes{\'u}s Miguel Garc{\'i}a-Foncillas},
  booktitle={Medicine},
  year={2015}
}
Biliopancreatic cancer is one of the most aggressive solid neoplasms, and incidence is rising worldwide. It is known that ATF6α is one of the transmembrane proteins that acts crucially in endoplasmic reticulum stress response, and knockdown induces apoptosis of pancreatic cells. Apart from this, p-p38 has been previously correlated with better outcome in… CONTINUE READING